Last reviewed · How we verify

Prevention of Kidney Transplant Rejection — Treatment Landscape & Competitive Intelligence

Prevention of Kidney Transplant Rejection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Kidney Transplant Rejection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Afinitor everolimus Novartis Kinase Inhibitor [EPC] Serine/threonine-protein kinase mTOR 2009-01-01
Mycophenolate MYCOPHENOLIC ACID Novartis Antimetabolite Immunosuppressant Inosine-5'-monophosphate dehydrogenase 2 2004-01-01
Rapamune sirolimus Pfizer mTOR Inhibitor Immunosuppressant [EPC] Serine/threonine-protein kinase mTOR 1999-01-01
Cellcept MYCOPHENOLATE MOFETIL Roche Palo Antimetabolite Immunosuppressant Inosine-5'-monophosphate dehydrogenase 2 1995-01-01
Prograf TACROLIMUS Astellas Pharma Calcineurin Inhibitor Immunosuppressant Interferon gamma 1994-01-01
Sandimmune cyclosporine Novartis AG (originally Sandoz) Calcineurin inhibitor (immunosuppressant) Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2 1983-11-14
Sandimmune Ciclosporin Novartis Calcineurin Inhibitor Immunosuppressant [EPC] Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform 1983-01-01
Imuran AZATHIOPRINE Legacy Pharma Purine Antimetabolite [EPC] ATP-binding cassette sub-family G member 2 1968-01-01
Rapamycin Rapamycin Institut National de la Santé Et de la Recherche Médicale, France Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2
Mycophenolate Mycophenolate Sanofi Inosine-5'-monophosphate dehydrogenase 1, Inosine-5'-monophosphate dehydrogenase 2, Inosine-5'-monophosphate dehydrogenase (IMPDH)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novartis · 3 drugs in Prevention of Kidney Transplant Rejection
  2. Central European Society for Anticancer Drug Research · 1 drug in Prevention of Kidney Transplant Rejection
  3. Hospices Civils de Lyon · 1 drug in Prevention of Kidney Transplant Rejection
  4. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in Prevention of Kidney Transplant Rejection
  5. Karolinska University Hospital · 1 drug in Prevention of Kidney Transplant Rejection
  6. Legacy Pharma · 1 drug in Prevention of Kidney Transplant Rejection
  7. Novartis AG (originally Sandoz) · 1 drug in Prevention of Kidney Transplant Rejection
  8. Novartis Pharmaceuticals · 1 drug in Prevention of Kidney Transplant Rejection
  9. Pfizer · 1 drug in Prevention of Kidney Transplant Rejection
  10. Roche Palo · 1 drug in Prevention of Kidney Transplant Rejection
  11. Sanofi · 1 drug in Prevention of Kidney Transplant Rejection
  12. Astellas Pharma · 1 drug in Prevention of Kidney Transplant Rejection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Kidney Transplant Rejection:

Cite this brief

Drug Landscape (2026). Prevention of Kidney Transplant Rejection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-kidney-transplant-rejection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing